Entering text into the input field will update the search result below

Oligonucleotide Synthesis Market Size, Share, Growth, Emerging Trends, Major Players And Forecast To 2026

Sep. 06, 2021 1:28 AM ETCredence Systems Corp. (CMOS), CROS, NGS, PCR, UK, DHR, TMO, MRK, A
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • Oligonucleotide Synthesis Market: Premium Industry Insights.

According to the new market research report "Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global Forecast to 2026", published by MarketsandMarkets™, the market is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion in 2021, at a CAGR of 17.6% during the forecast period.

Browse in-depth TOC on "Oligonucleotide Synthesis Market"

236 – Tables

40 – Figures

246 – Pages

Download PDF Brochure:

Oligonucleotide Synthesis Market

The major factors driving the growth of Oligonucleotide Synthesis Market include the increasing use of synthesized oligos in therapeutic applications, increasing government funding, and the growing focus on personalized medicine.

The hospital segment accounted for the largest share of the end user segment in the market in 2020.

Based on end users, the oligonucleotide synthesis market is categorized into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOS) & contract research organizations (CROS), and academic & government institutes. In 2020, Hospitals accounted for the largest share of the market. Growth in this market is largely driven by the significant number of inpatient & outpatient visits in hospitals and the high requirement of oligonucleotide drugs to cater to the growing demand of patients suffering from rare diseases, neurological disorders, and infectious diseases.

The PCR sub segment accounted for the largest share of the research application segment in the oligonucleotide synthesis market in 2020.

Based on application, the market is segmented into therapeutic, research and diagnostic applications. The research application segment is further segmented into, PCR, sequencing and other research applications. In 2020, PCR sub segment accounted for the largest share of the research application segment in the market. PCR technologies such as qPCR are highly sensitive and cost-effective which drive the market growth for PCR. These PCR applications utilize sequence-specific primers, thus boosting the market for oligos (which are used as probes and primers) in the PCR market.

Request Sample Pages:

Oligonucleotide Synthesis Market

The Asia Pacific region is the fastest growing region of the oligonucleotide synthesis market in 2020.

In 2020, the Asia Pacific region accounted for the fasted growing region of the market. Factors such as growing R&D funding, rising product availability, lower outsourcing costs, increasing research activities, increasing applications of oligos in molecular diagnostics & therapeutics, and the rising awareness of oligonucleotides are expected to drive market growth.

Some of the leading players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), and Agilent Technologies, Inc. (US). The leading players in the oligonucleotide therapeutics market are Biogen Inc. (US) and Sarepta Therapeutics, Inc. (US).

Browse Related Reports:

Genomics Market by Product & Service (System & Software, Consumables, Services), Technology (Sequencing, PCR), Application (Drug Discovery & Development, Diagnostic, Agriculture), End User (Hospital & Clinics, Research Centers) – Global Forecast to 2025


Next-generation Sequencing (NGS) Market by Product (NOVASEQ, NEXTSEQ, SEQUEL, NANOPORE), Consumables, Bioinformatics, Services (EXOME, RNA, DENOVO), Technology (ION, SMRT), Application (Diagnostics, Cancer), End User, Region - Global Forecast to 2025

Next-generation Sequencing Market - Global Forecast to 2026 | MarketsandMarkets

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.


Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.